Efficient repair of human genetic defect by CRISPR/Cas9-mediated interlocus gene conversion

Abstract

DNA double-strand breaks (DSBs) induced by gene-editing tools are primarily repaired through non-homologous end joining (NHEJ) or homology-directed repair (HDR) using synthetic DNA templates. However, error-prone NHEJ may result in unexpected indels at the targeted site. For most genetic disorders, precise HDR correction using exogenous homologous sequence is ideal. But, the therapeutic application of HDR might be especially challenging given the requirement for the codelivery of exogenous DNA templates with toxicity into cells, and the low efficiency of HDR could also limit its clinical application. In this study, we efficiently repair pathogenic mutations in HBB coding regions of hematopoietic stem cells (HSCs) using CRISPR/Cas9-mediated gene conversion (CRISPR/GC) using the paralog gene HBD as the internal template. After transplantation, these edited HSCs successfully repopulate the hematopoietic system and generate erythroid cells with significantly reduced thalassemia propensity. Moreover, a range of pathogenic gene mutations causing β-thalassemia in HBB coding regions were effectively converted to normal wild-type sequences without exogenous DNA templates using CRISPR/GC. This highlights the promising potential of CRISPR/GC, independent of synthetic DNA templates, for genetic disease gene therapy.

Keywords

CRISPR / gene conversion / gene therapy / β-thalassemia / hematopoietic stem cells

References

[1] El-Kenawy A, Benarba B, Neves AF, et al. Gene surgery: potential applications for human diseases. EXCLI J 2019;18:908–30.

[2] Lau CH. Applications of CRISPR-Cas in bioengineering, biotechnology, and translational research. CRISPR J 2018;1:379–404.

[3] Papasavva P, Kleanthous M, Lederer CW. Rare opportunities: CRISPR/Cas-based therapy development for rare genetic diseases. Mol Diagn Ther 2019;23:201–22.

[4] Romero Z, Lomova A, Said S, et al. Editing the sickle cell disease mutation in human hematopoietic stem cells: comparison of endonucleases and homologous donor templates. Mol Ther 2019;27:1389–406.

[5] Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol 2020;10:1387.

[6] Humbert O, Radtke S, Samuelson C, et al. Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. Sci Transl Med 2019;11:762–75.

[7] Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 2018;36:765–71.

[8] Antoniani C, Meneghini V, Lattanzi A, et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human beta-globin locus. Blood 2018;131:1960–73.

[9] Canver MC, Smith EC, Sher F, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 2015;527:192–7.

[10] Khosravi MA, Abbasalipour M, Concordet JP, et al. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: a promising approach for gene therapy of beta thalassemia disease. Eur J Pharmacol 2019;854:398–405.

[11] Liu N, Hargreaves VV, Zhu Q, et al. Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch. Cell 2018;173:430–442.e17.

[12] Wu Y, Zeng J, Roscoe BP, et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 2019;25:776–83.

[13] Chen JM, Cooper DN, Chuzhanova N, et al. Gene conversion: mechanisms, evolution and human disease. Nat Rev Genet 2007;8:762–75.

[14] Sharon D, Glusman G, Pilpel Y, et al. Primate evolution of an olfactory receptor cluster: diversification by gene conversion and recent emergence of pseudogenes. Genomics 1999;61:24–36.

[15] Woelk CH, Frost SD, Richman DD, et al. Evolution of the interferon alpha gene family in eutherian mammals. Gene 2007;397:38–50.

[16] Liang D, Mikhalchenko A, Ma H, et al. Limitations of gene editing assessments in human preimplantation embryos. Nat Commun 2023;14:1219.

[17] Wu Y, Liang D, Wang Y, et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 2013;13:659–62.

[18] Slightom JL, Blechl AE, Smithies O. Human fetal G gamma- and A gamma-globin genes: complete nucleotide sequences suggest that DNA can be exchanged between these duplicated genes. Cell 1980;21:627–38.

[19] Adams JG 3rd, Morrison WT, Steinberg MH. Hemoglobin Parchman: double crossover within a single human gene. Science 1982;218:291–3.

[20] Bothmer A, Phadke T, Barrera LA, et al. Characterization of the interplay between DNA repair and CRISPR/Cas9-induced DNA lesions at an endogenous locus. Nat Commun 2017;8:13905.

[21] Javidi-Parsijani P, Lyu P, Makani V, et al. CRISPR/Cas9 increases mitotic gene conversion in human cells. Gene Ther 2020;27:281–96.

[22] Origa R. beta-Thalassemia. Genet Med 2017;19:609–19.

[23] Thein SL. The molecular basis of beta-thalassemia. Cold Spring Harb Perspect Med 2013;3:a011700.

[24] Cosenza LC, Gasparello J, Romanini N, et al. Efficient CRISPR-Cas9-based genome editing of beta-globin gene on erythroid cells from homozygous beta(0)39-thalassemia patients. Mol Ther Methods Clin Dev 2021;21:507–23.

[25] DeWitt MA, Magis W, Bray NL, et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med 2016;8:360–ra134.

[26] Manchinu MF, Marongiu MF, Poddie D, et al. In vivo activation of the human delta-globin gene: the therapeutic potential in beta- thalassemic mice. Haematologica 2014;99:76–84.

[27] Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110–20.

[28] McIntosh BE, Brown ME, Duffin BM, et al. Nonirradiated NOD,B6. SCID Il2rgamma-/- Kit(W41/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells. Stem Cell Rep 2015;4:171–80.

[29] Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 2014;30:1473–5.

[30] Clement K, Rees H, Canver MC, et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol 2019;37:224–6.

[31] Dorschner MO, Hawrylycz M, Humbert R, et al. High-throughput localization of functional elements by quantitative chromatin profiling. Nat Methods 2004;1:219–25.

[32] Haapaniemi E, Botla S, Persson J, et al. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med 2018;24:927–30.

[33] Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014;510:235–40.

[34] Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901–10.

[35] Tan JA, Chin PS, Wong YC, et al. Characterisation and confirmation of rare beta-thalassaemia mutations in the Malay, Chinese and Indian ethnic groups in Malaysia. Pathology (Phila) 2006;38:437–41.

[36] Tan JA, Tan KL, Omar KZ, et al. Interaction of Hb South Florida (codon 1; GTG→ATG) and HbE, with beta-thalassemia (IVS1-1; G→A): expression of different clinical phenotypes. Eur J Pediatr 2009;168:1049–54.

[37] Innan H. A two-locus gene conversion model with selection and its application to the human RHCE and RHD genes. Proc Natl Acad Sci U S A, 2003;100:8793–8.

[38] Fantuzzi L, Tagliamonte M, Gauzzi MC, et al. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cellular and molecular life sciences 2019;76:4869–86.

RIGHTS & PERMISSIONS

The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.